Highlights in the biotech sector last week include a favorable court ruling for United Therapeutics’ (UTHR) in a patent infringement case, positive late-stage data on Repros Therapeutics’ (RPRX) testosterone replacement treatment and the filing of the first Biologics License Application (BLA) for a PCSK9 inhibitor. United Therapeutics scored a huge win in its patent infringement…
Buying bitcoin from exchanges can involve lots of hoop-jumping, as customers navigate complex and tedious registration and transaction processes. Some people are now cutting through the whole tangled mess, and having their employers pay them in bitcoin directly. Wagepoint, a startup based in Waterloo and Nova Scotia, Canada, offers Canadian and US companies an easy…
Microsoft Corporation (NASDAQ MSFT) is planning to revamp MSN, catching up with CEO Satya Nadella’s “mobile first, cloud first” strategy. The company will unveil various MSN apps for Apple and Android devices shortly. Microsoft will roll-out almost completely revamped MSN by adding new content, popular apps and productivity tools. MSN new home page displays shred…
Google Inc (NASDAQ GOOG) appointed a panel that will carry its first meeting on Tuesday discussing over the fine tuning between privacy and the free flow of information following the May court ruling that ordered the search engine giant to abide by “Right to be forgotten” rule. Google would host its first meeting session, where…
Facebook Inc (NASDAQ FB) is adding a new video features that are similar to YouTube for which the update will be launched soon. On an average, more than 1 billion videos are launched on Facebook per day since June, which is an increase of 50% from May and through July of this year, according to…
BioMarin Pharmaceutical (BMRN) lowered its guidance for 2014 revenues after a thorough evaluation of its transaction with Regeneron Ireland, an indirect, wholly owned subsidiary of Regeneron Pharmaceuticals. Along with its earnings release last month BioMarin had announced the sale of the rare pediatric disease priority review voucher for $67.5 million to Regeneron. The biopharmaceutical company…
